Covid-19 Update

Vicky Foxcroft Excerpts

Wednesday 30th December 2020 Commons Chamber

[Matt Hancock]

I want to thank Nigel Watson and all his colleagues who have delivered this fantastic effort across Hampshire. It is true that the current rate-limiting factor on the roll-out of the vaccine is the supply of the approved vaccine. Not only do we need to have it manufactured and in the country, but each batch needs to be checked, because it has to be in pristine condition. The worst thing we could do is inject someone with something that we think is vaccine, but does not work because it has not been stored properly. That takes time.

We have 530,000 doses of the AstraZeneca jab ready to go, and they will be deployed from Monday. In addition, we have over 3 million doses of the Pfizer vaccine that are ready, because we needed to hold one dose back. Once we move to the 12-week window for dosage—for the Pfizer vaccine, too—which has been recommended today by the regulator and by the Joint Committee on Vaccination and Immunisation, we will be able to roll those out. That will happen through January, rather than immediately. The end result of all that is that we can significantly accelerate the roll-out of the vaccine programme.

[Vicky Foxcroft (Lewisham, Deptford) (Lab) [V]]

I have asked the Secretary of State on several occasions for a timetable for the roll-out of the vaccination programme. Now that, thankfully, the AstraZeneca vaccine has been approved, can he provide some certainty and a timetable that prioritises unpaid carers, given that many of them care for extremely vulnerable people? He has been asked for that several times today, and people really need hope to carry on in these difficult times.

[Matt Hancock]

I totally understand why people want the answer to that question, because of the hope that the vaccine gives us. What I can tell the hon. Lady is that the speed of the roll-out will be determined by the speed of manufacture. While we have 530,000 doses ready to go from Monday, we also need to make sure that we receive more approved doses. We are working closely with AstraZeneca on that, as we have with Pfizer. That is what will determine the speed of the roll-out. The NHS has a plan, and it is ready to go.